Lumenis Announces Participation in First Educational Course at the 17th European Burns Association Congress
September 26, 2017 – Yokneam, Israel
Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced it will be the first laser company to participate in the European Burn Association’s Educational course on ‘Post Burn Reconstruction’ at the 17th European Burn Association (EBA) Congress, being held in Birmingham, U.K. from September 26-27, 2016.
“In the past decade and a half, there have been major strides in the management of severe scars, especially with the increased adoption of laser therapy approaches,” said Gerd Gauglitz, M.D., dermatologist at the Department of Dermatology and Allergology, Ludwig Maximilians University, Munich, Germany. “Laser scar therapy, particularly the Lumenis UltraPulse™ SCAAR FX™ fractional CO2 ablative laser, has proven to be a significant advancement in scar treatment and management and has been progressively embraced as a promising tool in the multidisciplinary treatment of complex burns and traumatic scars.”
EBA attendees are invited to attend the educational symposium featuring Dr. Gauglitz, who will share his experience of burn scar treatments with UltraPulse SCAAR FX and conduct live demonstrations of the procedure with two burn scar patients:
Educational Symposium with Live Demos “Ablative fractional laser for the improvement of hypertrophic burn scars with UltraPulse” will take place on 26 September at 08:40 – 10:10
and will be led by Dr. Gerd Gauglitz.
Since its introduction, the UltraPulse platform has improved the quality of care and life for scar patients all over the world. The innovative UltraPulse SCAARFX technology is becoming the standard of care for severe scar patients around the world and has been used in many humanitarian missions, to treat wounded warriors and war survivors. The technology is also being used to treat Kim Phuc, a survivor of the Vietnam War bombing, also recognized as “The Girl in the Picture.”
“We are proud to be the first energy-based technology company to participate in the European Burn Association Congress Educational Course,” said Tzipi Ozer-Armon, CEO of Lumenis. “It is an honor to partner and collaborate with the organization to help educate dermatologists about the latest treatment advancements and to develop technology to further enhance the care for burn patients everywhere.”
At EBA, Lumenis will offer conference participants the opportunity to register to win a preceptorship, featuring a full day of hands-on training with the UltraPulse SCAAR FX from leading industry experts in Europe. For more information about the preceptorship opportunity, please visit http://information.lumenis.com/eba-course-ultrapulse-with-scaarfx.
For more about the Lumenis’ family of fractional ablative laser resurfacing products and its portfolio of innovative scar treatment solutions, please visit the Lumenis booth #15 at the conference.
Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com
Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company’s plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management’s current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Lazar Partners Ltd.
PB-2007437 rev A